Videos

Dr Hatfield shares a case of a patient living in shared housing who was concerned about her housemates seeing her PrEP medication.

Amesh Adalja, MD, infectious disease physician, outlines effective communication strategies that respect patient concerns while reinforcing physician credibility.

Multiple lab options can lead to incorrect UACR testing. Clear ordering practices are essential for actionable results.

Gus Alva, MD, previews 2026 research directions and explains why sleep assessment and sleep disorders may become a bigger focus in routine care.

Gus Alva, MD, reviews the current clinical research landscape for psychedelics and discusses how PCPs can effectively counsel patients on safety and expectations.

Psychiatrist Gus Alva, MD, discusses newer, faster depression screening approaches that primary care clinicians can implement.

From staff training to scheduling flexibility, a primary care physician shares practical insights on integrating long-acting injectable PrEP into routine care.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes.

Injection anxiety and concerns about side effects are common. A primary care physician outlines practical counseling strategies, expectation-setting, and interventions that improve patient comfort and confidence.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Panelists discuss how advancing NK receptor research is reshaping menopause care, emphasizing education, innovation, and patient empowerment for lasting impact.

Panelists discuss how structured monitoring and interdisciplinary collaboration enable safe, effective integration of NK-targeted therapies into primary care.

Gus Alva, MD, reviews key 2025 psychiatry advances, including non-monoaminergic approaches to MDD and newer targets in schizophrenia care.

Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.

Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.

Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.

Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.

Larkin Larkin, MD, reviews treatment options for VMS, comparing hormone therapy effectiveness with antidepressants and new neurokinin antagonists.

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.